|
Category:
|
Nuclear Receptors PPAR Receptors
|
|
Cat.No.
|
Product Name
|
|
2022 |
SR 202
|
| Alternative name(s): |
Mifobate |
|
|
Price and Availability
Click here for full price details of
SR 202
|
|
Chemical Name:
(4-Chlorophenyl)(dimethoxyphosphinyl)methyl phosphoric
acid dimethyl ester |
|
|
Biological Activity:
Selective
PPARγ antagonist; antidiabetic and antiobesity agent. Attenuates
troglitazone-induced PPARγ transcriptional activity (IC50
= 140 μM) without affecting ligand-stimulated PPARα, PPARβ or FXR transcriptional activity.
Inhibits PPARγ-dependent adipocyte differentiation
and growth in vitro and in vivo. Improves insulin sensitivity in diabetic ob/ob
mice and increases HDL levels in rats in vivo.
|
Technical Data:
|
|
|
Resources:
|
|
Certificate of Analysis / MSDS:
Certificate of Analysis is currently unavailable on-line. Please contact Customer Service
|
|
|
References:
Nguyen et al ((1987)
gem-Diphosphonate and gem-phosphonate-phosphate compounds with
specific high density lipoprotein inducing activity. J.Med.Chem. 30
1426. Rieusset et al (2002) A new selective peroxisome
proliferator-activated receptor γ
antagonist with antiobesity and antidiabetic activity. Mol.Endocrinol. 16
2628. Doggrell (2003) Do peroxisome proliferation receptor-g antagonists have clinical potential
as combined antiobesity and antidiabetic drugs? Expert Opin.Invest.Drugs 12
713.
|
|
View related products by Pharmacological Action
or by Research Area
Keywords: SR 202, PPAR Receptors, Selective PPARg Antagonist; Antidiabetic & Antiobesity Agent, Mifobate, SR202, Tocris Bioscience
|
